Roles of Concurrent Chemo-Radiotherapy and Radiotherapy Alone in the Management of Malignancies of Head and Neck In a Tertiary Care Hospital
Authors/Creators
- 1. Associate Professor of Radiation Oncology, Department of Radiation Oncology, Viswabharathi Medical College and Hospital, Kurnool, Andhra Pradesh
- 2. Assistant Professor of Radiation Oncology, Department of Radiation Oncology Viswabharathi Medical College and Hospital, Kurnool, Andhra Pradesh
- 3. Consultant, Radiation Oncology, Department of Radiation Oncology, Karnataka Cancer Center
Description
Background: Optimization of dose of radiation therapy (RT), fractionation, normal-tissue sparing, and technology has helped treating malignancies of the Head and Neck. Introduction of the combination of chemotherapy and radiotherapy has increased the tumor control and preservation of organ integrity. This study compares the final outcome of these two methods in treating the Head and neck cancers. Aim of the study: To compare the outcome of the advanced stages of Head and neck malignancies with concurrent chemo-radiation and radiation alone in terms locoregional control (tumor regression), recurrence, survival and complications. Materials: A randomized prospective study was conducted between Jan 2018 to Dec 2020 in the Department of Radiation Oncology, Viswabharathi Medical College and General Hospital, a tertiary teaching Hospital in Kurnool, Andhra Pradesh. 63 patients with advanced stages (stage III and IV) of Head and Neck Malignancies were included. Group A (33) patient with Head and Neck malignancies treated with Radiotherapy alone and Group B (30) patients treated with Concurrent chemotherapy and Radiotherapy. Patients to both the groups were allotted by a random number generated online at randomnumber.com. Patients diagnosed aged above 18 years were included. Patients of both the genders were included. Patients with histology of the tumors showing as squamous cell carcinoma were included. Patients with unresectable tumors were included. Patients with advanced stages (stage III and IV) were included. Patients with Eastern Cooperative Oncology Group (ECOG), (21), 1982 performance status between 0 and 02 were included. Results: 63 patients Head and Neck malignancies were grouped as A (33) and B (30) patients. Group A received EBRT alone and B group concurrent chemo-radiation. There were 22 (34.92%) male patients in group A and 20 (31.74%) male patients in group B and there were 11 (17.46%) female patients in group A and 10 (15.87%) female patients in group B. The mean age in group A was 56.78±4.70 years and the mean age in the group B was 54.30±5.15 years. The age and gender, ECOG status, TNM staging and gross staging of the malignant diseases observed in the patients of both the groups included in this study had no statistical significant difference. (p- Value more than 0.05). Conclusions: The advantage of Combine chemo-radiation versus Radiotherapy alone was found to be only marginal and failed to show any positive significant advantage of concurrent chemo-radiotherapy over EBRT alone. In terms of overall response rates at the end of 06 months was ranging from 85.3% to 93% in the study. The limitations to this study are relatively short follow-up and small sample size.
Abstract (English)
Background: Optimization of dose of radiation therapy (RT), fractionation, normal-tissue sparing, and technology has helped treating malignancies of the Head and Neck. Introduction of the combination of chemotherapy and radiotherapy has increased the tumor control and preservation of organ integrity. This study compares the final outcome of these two methods in treating the Head and neck cancers. Aim of the study: To compare the outcome of the advanced stages of Head and neck malignancies with concurrent chemo-radiation and radiation alone in terms locoregional control (tumor regression), recurrence, survival and complications. Materials: A randomized prospective study was conducted between Jan 2018 to Dec 2020 in the Department of Radiation Oncology, Viswabharathi Medical College and General Hospital, a tertiary teaching Hospital in Kurnool, Andhra Pradesh. 63 patients with advanced stages (stage III and IV) of Head and Neck Malignancies were included. Group A (33) patient with Head and Neck malignancies treated with Radiotherapy alone and Group B (30) patients treated with Concurrent chemotherapy and Radiotherapy. Patients to both the groups were allotted by a random number generated online at randomnumber.com. Patients diagnosed aged above 18 years were included. Patients of both the genders were included. Patients with histology of the tumors showing as squamous cell carcinoma were included. Patients with unresectable tumors were included. Patients with advanced stages (stage III and IV) were included. Patients with Eastern Cooperative Oncology Group (ECOG), (21), 1982 performance status between 0 and 02 were included. Results: 63 patients Head and Neck malignancies were grouped as A (33) and B (30) patients. Group A received EBRT alone and B group concurrent chemo-radiation. There were 22 (34.92%) male patients in group A and 20 (31.74%) male patients in group B and there were 11 (17.46%) female patients in group A and 10 (15.87%) female patients in group B. The mean age in group A was 56.78±4.70 years and the mean age in the group B was 54.30±5.15 years. The age and gender, ECOG status, TNM staging and gross staging of the malignant diseases observed in the patients of both the groups included in this study had no statistical significant difference. (p- Value more than 0.05). Conclusions: The advantage of Combine chemo-radiation versus Radiotherapy alone was found to be only marginal and failed to show any positive significant advantage of concurrent chemo-radiotherapy over EBRT alone. In terms of overall response rates at the end of 06 months was ranging from 85.3% to 93% in the study. The limitations to this study are relatively short follow-up and small sample size.
Files
IJPCR,Vol15,Issue9,Article48.pdf
Files
(377.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:ae250a59878cc9674f9f10ae9ec9bf21
|
377.2 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-08-30
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue9,Article48.pdf
- Development Status
- Active
References
- 1. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr/(3 December 2011, date last accessed). 2. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996; 88: 890–899. 3. Posner MR, Haddad RI, Wirth L et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol. 2004; 31: 778–785. 4. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008; 359: 1143–1154. 5. Pignon JP, Le MA, Maillard E et al. Metaanalysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92(1): 4–14. 6. Vigneswaran N, Williams MD. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am. 2014; 26: 123–141. 7. Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma--an update. CA Cancer J Clin. 2015; 65: 401–421. 8. Rosenthal, D.I.; Mohamed, A.S.R.; Garden, A.S.; Morrison, W.H.; El-Naggar, A.K.; Kamal, M.; Weber, R.S.; Fuller, C.D.; Peters, L.J. Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients with Head and Neck Cancer. Int. J. Radiat. Oncol. Biol. Phys.2017;5: 1002–1011. 9. Alsahafi, E.; Begg, K.; Amelio, I.; Raulf, N.; Lucarelli, P.; Sauter, T.; Tavassoli, M. Clinical update on head and neck cancer: Molecular biology and ongoing challenges. Cell Death Dis.2019;10: 1–17. 10. Wan, J.T.; Sheeley, D.M.; Somerman, M.J.; Lee, J.S. Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors. Bone Res.2020;8: 1–12. 11. Barton MB, Jacob S, Shafiq J, Wong K, Thompson SR, Hanna TP, Delaney GP.. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol 2014; 112: 140–144. 12. Saloura V, Langerman A, Rudra S, Chin R, Cohen EE. Multidisciplinary care of the patient with head and neck cancer. Surg Oncol Clin N Am. 2013; 22: 179–215. 13. Van der Molen L, van Rossum MA, Burkhead LM, Smeele LE, Hilgers FJ. Functional outcomes and rehabilitation strategies in patients treated with chemoradiotherapy for advanced head and neck cancer: a systematic review. Eur Arch Otorhinolaryngology. 2009; 266: 889–900. 14. Mallick I, Waldron JN. Radiation therapy for head and neck cancers. Semin Oncol Nurs. 2009; 25: 193–202. 15. Grégoire V, Langendijk JA, NuytsS. Advances in Radiotherapy for Head and Neck Cancer. J Clin Oncol. 2015; 33: 3277–3284. 16. régoire V, Langendijk JA, Nuyts S. Advances in Radiotherapy for Head and Neck Cancer. J Clin Oncol. 2015; 33: 3277–3284. 17. Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, et al.. Head and neck cancers. J Natl ComprCancNetw. 2011; 9: 596–650. 18. Duprez F, Madani I, Bonte K, Boterberg T, Vakaet L, Derie C, et al.. Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory. Radiother Oncol. 2009; 93: 563–569. 19. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Medical Care. 2002; 40: IV–49. 20. Barton MB, Jacob S, Shafiq J, Wong K, Thompson SR, Hanna TP, Delaney GP.. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol. 2014; 112: 140–144. 21. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec; 5(6):649-655. 22. Mendenhall, W.M.; Hinerman, R.W.; Amdur, R.J.; Malyapa, R.S.; Lansford, C.D.; Werning, J.W.; Villaret, D.B. Postoperative radiotherapy for squamous cell carcinoma of the head and neck. Clin. Med. Res.2006;4: 200–208. 23. Overgaard, J.; Mohanti, B.K.; Begum, N.; Ali, R.; Agarwal, J.P.; Kuddu, M.; Bhasker, S.; Tatsuzaki, H.; Grau, C. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA study): A randomized, multicenter trial. Lancet Oncol.2010;6:553–560. 24. Rosenthal, D.I.; Mohamed, A.S.R.; Garden, A.S.; Morrison, W.H.; El-Naggar, A.K.; Kamal, M.; Weber, R.S.; Fuller, C.D.; Peters, L.J. Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients with Head and Neck Cancer. Int. J. Radiat. Oncol. Biol. Phys.2017;5: 1002–1011. 25. Coffey, A.M.D.; Ghanem, T.P.D. AHNS Cancer of the Oropharynx: Risk Factors, Diagnosis, Treatment, and Outcomes, 7th ed.;Maghami, E.M.D., Ed.; American Head & Neck Society Education Committee: Rochester, NY, USA, 2016. 26. Viens, L.J.; Henley, S.J.; Watson, M.; Markowitz, L.E.; Thomas, C.C.; Thompson, T.D.; Razzaghi, H.; Saraiya, M. Centers for Disease Control and Prevention (CDC). Human papillomavirus–associated cancers— United States, 2008–2012. Morb. Mortal. Wkly. Rep.2016;65: 661–666. 27. Marur, S.; Li, S.; Cmelak, A.J.; Gillison, M.L.; Zhao, W.J.; Ferris, R.L.; Westra, W.H.; Gilbert, J.; Bauman, J.E.; Wagner, L.I.; et al. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOGACRIN Cancer Research Group. J. Clin. Oncol.2017;35: 490–497. 28. Bourhis J, Le Maıˆtre A, Baujat B et al. Individual patients' data meta-analyses in head and neck cancer. CurrOpin Oncol 2007; 19: 188–194. 29. Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancer: a study by the Gruppo di Studio SuiTumoridella Testa e del Collo. J Natl Cancer Inst 1994; 86: 265–272.